Exxell BIO

Exxell Bio is a clinical-stage biotechnology company dedicated to the development of innovative vaccines for the prevention and treatment of infectious diseases, specifically targeting rabies. The company's lead program, EXL-001, is a live-attenuated rabies vaccine candidate that utilizes a proprietary, highly attenuated viral platform licensed from Thomas Jefferson University. This technology aims to provide a more effective and accessible alternative to current rabies post-exposure prophylaxis, which typically requires multiple injections and expensive immunoglobulins. By focusing on rapid immune response and simplified dosing schedules, Exxell Bio seeks to reduce the global mortality associated with rabies infections. The company has received substantial support from the National Institutes of Health (NIH) to advance its clinical pipeline.